OC
Oculis Holding AG
OCS · NASDAQ
$9.27 +0.32% (+$0.03)
1M -24.08%
Market Cap CHF 445.5M
P/E Ratio -
Div. Yield -
ROE 42.92%
Bulios Fair Price
$7.02
24.3% downside
Current Price
$9.27
Undervalued Fair Value Overvalued
According to Bulios Fair Price, OCS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
4/9Valuation
44 /100
Fair P/S 1,833.44x
P/B 2.03x
P/E N/A
Growth
-
N/A EPS growth N/A
Rev. growth N/A
Book val. growth N/A
Profitability
14 /100
Weak Gross margin 35.21%
Net margin 32,780.20%
FCF margin 27,181.90%
Quality
0 /100
Poor ROIC 38.94%
ROE 42.92%
Asset turnover 0.00x
Debt
69 /100
Low Debt/Equity 0.01x
Current ratio 8.35x
Int. coverage -85.17x
Stability
4 /100
Unstable Beta 0.23x
EPS volatility 100.31%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about OCS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Riad Sherif
Employees
60
Headquarters
Zug
Upcoming events
05 NOV
Earnings
Upcoming earnings report